Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola
Cibus (NASDAQ: CBUS) has successfully completed gene edits in Canola for its 4th mode of action targeting Sclerotinia (White Mold) resistance trait, with greenhouse results expected in Q1 2025. This achievement follows positive field trial results from their 2nd mode of action, which demonstrated enhanced disease resistance. Sclerotinia is identified as the most significant disease affecting Canola yields and the second most impactful in Soybean. The company's approach involves developing multiple modes of action for durable disease resistance, with potential applications beyond Canola to other crops like Soybean.
Cibus (NASDAQ: CBUS) ha completato con successo le modifiche genetiche nella colza per il suo quarto meccanismo d'azione mirato alla resistenza alla Sclerotinia (muffa bianca), con risultati in serra attesi nel primo trimestre del 2025. Questo risultato segue gli esiti positivi delle prove sul campo del loro secondo meccanismo d'azione, che ha dimostrato una resistenza migliorata alle malattie. La Sclerotinia è identificata come la malattia più significativa che influisce sulle rese della colza e la seconda più impattante nella soia. L'approccio dell'azienda prevede lo sviluppo di più meccanismi d'azione per una resistenza durevole alle malattie, con potenziali applicazioni oltre la colza ad altre colture come la soia.
Cibus (NASDAQ: CBUS) ha completado con éxito las ediciones genéticas en canola para su cuarto modo de acción que apunta a la resistencia a la Sclerotinia (moho blanco), con resultados en invernadero esperados para el primer trimestre de 2025. Este logro sigue a resultados positivos de ensayos de campo de su segundo modo de acción, que demostró una resistencia mejorada a enfermedades. La Sclerotinia se identifica como la enfermedad más significativa que afecta los rendimientos de canola y la segunda más impactante en soja. El enfoque de la compañía implica desarrollar múltiples modos de acción para una resistencia durable a enfermedades, con posibles aplicaciones que van más allá de la canola a otros cultivos como la soja.
Cibus (NASDAQ: CBUS)는 Sclerotinia (흰곰팡이) 저항성 형질을 목표로 하는 네 번째 작용 모드에서 카놀라의 유전자 편집을 성공적으로 완료했으며, 온실 결과는 2025년 1분기에 예상됩니다. 이 성과는 두 번째 작용 모드의 긍정적인 필드 시험 결과를 뒤따르며, 질병 저항성이 향상된 것을 보여주었습니다. Sclerotinia는 카놀라 수확량에 영향을 미치는 가장 중요한 질병으로 식별되며, 대두에서는 두 번째로 영향력이 큽니다. 회사의 접근 방식은 지속 가능한 질병 저항성을 위해 여러 작용 모드를 개발하는 것을 포함하며, 카놀라 외에 대두와 같은 다른 작물에도 적용될 가능성이 있습니다.
Cibus (NASDAQ: CBUS) a réussi à compléter des modifications génétiques dans le colza pour son quatrième mode d'action visant à la résistance à la Sclerotinia (moisissure blanche), avec des résultats en serre attendus pour le premier trimestre 2025. Cette réalisation fait suite à des résultats positifs d'essais en champ de leur deuxième mode d'action, qui a montré une résistance accrue aux maladies. La Sclerotinia est identifiée comme la maladie la plus significative affectant les rendements du colza et la deuxième plus impactante dans le soja. L'approche de l'entreprise implique le développement de plusieurs modes d'action pour une résistance durable aux maladies, avec des applications potentielles au-delà du colza vers d'autres cultures comme le soja.
Cibus (NASDAQ: CBUS) hat erfolgreich Genbearbeitungen in Raps für den vierten Wirkmechanismus zur Zielrichtung der Resistenz gegen Sclerotinia (Weißer Schimmel) abgeschlossen, wobei Ergebnisse aus dem Gewächshaus im ersten Quartal 2025 erwartet werden. Dieser Erfolg folgt auf positive Ergebnisse aus Feldversuchen ihres zweiten Wirkmechanismus, der eine verbesserte Krankheitsresistenz zeigte. Sclerotinia wird als die bedeutendste Krankheit identifiziert, die die Erträge von Raps beeinflusst und die zweitschädlichste in Sojabohnen ist. Der Ansatz des Unternehmens beinhaltet die Entwicklung mehrerer Wirkmechanismen für eine dauerhafte Krankheitsresistenz, mit potenziellen Anwendungen über Raps hinaus auf andere Pflanzen wie Sojabohnen.
- Successfully completed gene edits for 4th mode of action in Sclerotinia resistance trait
- Previous field trials showed enhanced disease resistance for 2nd mode of action
- Technology demonstrates potential for application in multiple crops beyond Canola
- Greenhouse results for 4th mode of action not yet available until Q1 2025
Insights
This milestone in gene editing for Sclerotinia resistance represents significant progress in crop protection technology. The successful completion of the 4th mode of action edits in Canola is particularly noteworthy because multiple defense mechanisms are important for creating durable disease resistance. The development could substantially impact Cibus's revenue potential through licensing opportunities.
The technology's potential application extends beyond Canola to Soybean markets, which significantly expands the commercial opportunity. Sclerotinia's status as the most impactful disease in Canola and second most impactful in Soybean positions this advancement as a valuable solution for major crop markets. The expected greenhouse results in Q1 2025 will be a critical milestone for validating the technology's effectiveness.
This development strengthens Cibus's competitive position in the agricultural biotechnology sector. The company's business model of developing and licensing plant traits for royalties could see significant upside if the greenhouse trials prove successful. The addressable market is substantial, considering Canola and Soybean are major global crops with persistent disease challenges.
The technology's ability to accelerate trait development time could translate into faster time-to-market and earlier revenue generation compared to traditional breeding methods. Investors should monitor the Q1 2025 greenhouse results as a key catalyst for potential value creation.
Cibus has successfully made the edits in Canola associated with the Company’s 4th mode of action for its White Mold (Sclerotinia) trait
Builds upon Cibus’ progress with its Sclerotinia resistance trait in Canola after Field Trial results for its 2nd mode of action showed enhanced disease resistance
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has successfully completed edits in Canola for its 4th mode of action for its Sclerotinia resistance trait and expects greenhouse results in the first quarter of 2025. Multiple modes of action, which are akin to a plant’s defenses to disease, are critical for durable disease resistance. This advancement builds upon the Company’s previously announced field trial results for its 2nd mode of action showing enhanced resistance to Sclerotinia in Canola plants edited with Cibus’ Sclerotinia resistance trait.
Greg Gocal, PhD, Co-Founder, Executive Vice President and Chief Scientific Officer at Cibus, stated, “The advancement of our work to address Sclerotinia demonstrates how Cibus’ technology can accelerate the time to develop traits using complex edits to address needs in agriculture. Sclerotinia is the most impactful disease in Canola reducing yields and is the second most impactful disease in Soybean. While these modes of action are being developed for our Sclerotinia resistance trait in Canola, they have potential in many other crops such as Soybean.”
Today’s announcement represents a major development in the Company’s progress toward providing durable White Mold resistance. Cibus believes that each of its edits for four different modes of action associated with Sclerotinia are unique and address important aspects of the disease pathology.
Rory Riggs, Chairman and CEO added, “Cibus continues to make strong progress with its advanced trait milestones, including targeting gene edits that will provide plants with multiple modes of action against diseases like Sclerotinia. This approach is similar to the use of antivirals in the pharmaceutical industry, where Cibus is providing crops like Canola novel traits to fight off disease infection. Because plant pathogens can evolve rapidly, the Company believes that it is important to provide multiple modes of action to develop a trait that is broadly applicable and is durable over time.”
About Sclerotinia
Sclerotinia sclerotiorum is a fungal pathogen, that causes significant disease (stem rot) in oilseed crops. It affects 14
About Cibus
Cibus is a leading independent plant trait company that develops and licenses plant traits to seed companies for royalties. Cibus is not a seed company, but rather a technology company that uses its proprietary gene editing technology to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus’ strategy is focused on commercializing productivity traits for the world’s major row crops with large acreage such as: canola, rice, soybean, corn and wheat. The Company targets traits that help manage farmers’ seed productivity, economics and sustainability challenges such as weeds, disease, and insects. The United Nations estimates that the impacts from these challenges cost the global economy approximately
CIBUS CONTACTS:
INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
203-918-4347
FAQ
What milestone did Cibus (CBUS) achieve in Canola gene editing?
When will Cibus (CBUS) release greenhouse results for its 4th mode of action in Canola?
What disease is Cibus (CBUS) targeting with its gene editing technology in Canola?
